HealthcareFirms.com » Vaccines

PharmAthene, Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene’s lead product development programs include: SparVax(TM) a second generation recombinant protective antigen (rPA) anthrax vaccine, Third generation rPA anthrax vaccine, Valortim(R) a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and Protexia(R) a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents.

Nabi Biopharmaceuticals

admin — Sun, 21 Feb 2010 13:59:34 +0000

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(R) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland.

Novavax, Inc.

admin — Sun, 21 Feb 2010 13:59:34 +0000

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.

Inovio Biomedical Corporation

admin — Wed, 17 Feb 2010 12:38:22 +0000

Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company’s SynCon(TM) technology enables the design of universal vaccines capable of protecting against multiple – including newly emergent, unknown – strains of pathogens such as influenza. Inovio’s proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania, the National Microbiology Laboratory of the Public Health Agency of Canada, and the NIH’s Vaccine Research Center. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute, and HIV Vaccines Trial Network.

Idera Pharmaceuticals, Inc.

admin — Wed, 17 Feb 2010 12:38:22 +0000

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors (TLRs), which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for our internal development programs and our partnered programs, and generates opportunities for additional collaborative alliances.

Bio-Bridge Science Inc.

admin — Fri, 12 Feb 2010 22:52:39 +0000

Bio-Bridge Science is a biotech company focused on the commercial development of biological products for the prevention and treatment of human infectious diseases and production material in producing vaccines. We intend to develop and obtain regulatory approval for commercial sale of the following vaccines: an HIV vaccine (HIV-PV Vaccine I), a vaccine designed to prevent and treat infection by the human immunodeficiency virus, or HIV, an HPV vaccine, a colon cancer therapeutic vaccine and other related potential products. Also, we sell bovine serum, a major production material in producing vaccines, through our 51% owned subsidiary, XHBD. The HIV vaccine and colon cancer vaccine are based on the technology platform co-developed by Dr. Liang Qiao, our chief executive officer and an associate professor at Loyola University Chicago. The technology is owned by Loyola University. In June 2002, Loyola University exclusively licensed this technology to our subsidiary Bio-Bridge Science Corporation with respect to development and sales in the territories of People’s Republic of China, Japan and the United States.